HepaTx
- Company typePrivate
- Founded2016
- HeadquartersPalo Alto, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
HepaTx firmographics
Firmographics- Name
- HepaTx
- Legal name
- HepaTx Corporation
- Website
- https://hepatx.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
HepaTx industry classification
Industry- Product category
- Cell Therapy / Regenerative Medicine
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)
- akta.pro secondary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
Keywords
Where HepaTx is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
HepaTx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Cell Therapy Products: HepaTx is developing off-the-shelf stem cell-based therapies for late-stage liver disease. Once approved through FDA regulatory pathways, the company will generate revenue through sale of its Hx-001 cell therapy product to healthcare providers, hospitals, and transplant centers. The company is pursuing a strategy spanning niche indications with lower developmental costs and rapid regulatory approval paths to larger market chronic liver disease indications.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
HepaTx product offering
Product offeringCore offering
HepaTx is developing off-the-shelf allogeneic cell therapy products for late-stage liver disease, using proprietary SF-Hep Technology licensed from Stanford University to differentiate adipose-derived stem cells into hepatocyte-like cells. The lead candidate, Hx-001, is designed to replace dead and diseased liver cells as an alternative to liver transplantation, with a scalable manufacturing process enabling on-demand clinical availability.
Product overview
HepaTx is developing off-the-shelf cell therapies for liver disease using regenerative medicine technologies based on stem cells. The company's lead product is Hx-001, an administration of hepatocyte-like cells to replace dead and diseased liver cells, providing a potential alternative to liver transplant. The technology is licensed from Stanford University and enables scalable, allogeneic cell therapy that can be manufactured, banked, and distributed for on-demand availability. The pipeline spans initial niche indications with lower developmental costs to large market chronic liver disease indications including NASH, genetic diseases, and liver failure/cirrhosis.
Differentiator
Problem solved
Functional benefit
Products and services
- Hx-001 A hepatocyte-like cell therapy product designed to replace dead and diseased liver cells, derived from adipose-derived stem cells (ASCs) using HepaTx's SF-Hep Technology. Demonstrated properties characteristic of the hepatocyte lineage including ureagenesis, with immunomodulatory properties and preclinical evidence of modulating acute inflammatory response and reducing hepatocyte damage. Developed for use by healthcare providers treating late-stage liver disease as an alternative to liver transplantation.
Companies that use HepaTx
Customer profileSegments1 record
Ideal customer profiles1 record
HepaTx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
HepaTx partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered supporting and core.
- NamocellsupportingCollaboration on single cell genomics analysis for cell therapy to treat late-stage liver diseases. Namocell provided single cell isolation technology to support characterization and optimization of HepaTx's cell therapy products.
- Takara Bio USAsupportingThree-way collaboration with Namocell and HepaTx on single cell genomics analysis for cell therapy development. Takara Bio USA provided technologies supporting single cell analysis workflows for characterizing HepaTx's cell therapy candidates.
- Stanford UniversitycoreExclusive worldwide license from Stanford University covering the SF-Hep Technology for generating hepatocyte-like cells from stem cells. The technology was invented by Dr. Gary Peltz, Professor in the Department of Anesthesia at Stanford. HepaTx is on a path to a comprehensive IP portfolio including additional manufacturing technologies and therapeutic applications.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
HepaTx competitors and assessment
Company assessmentDirect peers
- Promethera Biosciences: Promethera develops allogeneic cell therapies derived from liver progenitor cells for liver disease and rare metabolic disorders. Direct competitor to HepaTx in the liver cell therapy space with similar allogeneic off-the-shelf strategy targeting end-stage liver disease and inborn errors of metabolism.
- LyGenesis: LyGenesis is developing a tissue-engineering approach to grow ectopic livers in lymph nodes as an alternative to liver transplantation. Directly comparable regenerative medicine strategy targeting the same end-stage liver failure population HepaTx addresses.
Broad incumbents
- Vertex Pharmaceuticals: Vertex has expanded beyond cystic fibrosis into cell and gene therapies including programs for metabolic liver diseases (e.g., alpha-1 antitrypsin deficiency). A well-capitalized incumbent pursuing adjacent liver indications with potentially competing or substitutive approaches to HepaTx's target indications.
- Pluristem Therapeutics: Pluristem develops placenta-derived allogeneic cell therapy products across multiple indications including liver disease. Comparable cell therapy platform with broader indication portfolio and similar allogeneic, off-the-shelf positioning as HepaTx.
- Vericel Corporation: Vericel is a commercial-stage cell therapy company (MACI, Epicel) with established cell therapy manufacturing, regulatory, and commercial infrastructure. Provides a reference point for what a scaled cell therapy business in regenerative medicine looks like, though focused on orthopedic and burn indications.
Emerging players
- Orgenesis: Orgenesis is developing autologous cell therapies and a decentralized cell therapy processing platform with relevance to liver and metabolic disease indications. Emerging player with overlapping cell therapy infrastructure and liver/metabolic disease focus.
- Sernova Corp: Sernova is developing cell therapy approaches using its Cell Pouch technology for chronic diseases including metabolic and liver-related conditions. Comparable regenerative medicine strategy combining cells with implantable delivery systems, addressing similar end-stage organ failure patient populations.
Others
- RoosterBio: RoosterBio provides mesenchymal stem cell (MSC) manufacturing tools and technologies that enable allogeneic cell therapy development. Relevant as an enabling/supply-chain partner whose MSC technologies could support HepaTx's adipose-derived stem cell manufacturing pipeline.
Market position
Strengths1 record
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
HepaTx social profiles
Digital presenceHepaTx financial estimates
Financial estimateRevenue estimate
Valuation estimate
HepaTx leadership team
Management profileNumber of profiles
Profiles4 records
HepaTx funding detail
Funding detailFunding overview
Funding rounds7 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HepaTx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HepaTx
What does HepaTx do?
HepaTx is developing off-the-shelf allogeneic cell therapy products for late-stage liver disease, using proprietary SF-Hep Technology licensed from Stanford University to differentiate adipose-derived stem cells into hepatocyte-like cells. The lead candidate, Hx-001, is designed to replace dead and diseased liver cells as an alternative to liver transplantation, with a scalable manufacturing process enabling on-demand clinical availability.
Is HepaTx a public or private company?
HepaTx is a private company. It is classified as venture growth investor backed and is currently operating.
When was HepaTx founded?
HepaTx was founded in 2016. It employs 1 to 10 people.
Where is HepaTx based?
HepaTx is headquartered in Palo Alto, United States, in the North America region.
How does HepaTx make money?
One revenue line is on record: cell Therapy Products.
Who are HepaTx's main competitors?
Direct peers on record are Promethera Biosciences and LyGenesis. Broad incumbents are Vertex Pharmaceuticals, Pluristem Therapeutics and Vericel Corporation. Emerging players are Orgenesis and Sernova Corp. RoosterBio is listed as an others.
Does HepaTx have an API?
No public API is recorded for HepaTx.
What industry is HepaTx in?
HepaTx's product category is Cell Therapy / Regenerative Medicine. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.